Sandra Patterson

International Bancshares reports steady half-year growth but a Q2 dip, revealing a strategy of proactive risk management and AI-driven efficiency.

A French biotech's breakthrough in topical mRNA delivery could turn skin into a programmable interface, disrupting dermatology and the multi-billion dollar beauty industry.

A recent pilot delivered a stunning 47% ROAS lift by breaking Google Shopping's visual formula. This is more than a metric—it's a new competitive playbook.

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

With the launch of its TED drug Lumvoa, Viridian Therapeutics steps into the commercial ring. But can early momentum and a deep pipeline justify the cost?

The geospatial intelligence firm hit a key inflection point, converting 259% revenue growth into its first profitable quarter on an operating basis.

Beyond the buzz, Wolters Kluwer's half-year results show its AI strategy is delivering real growth, fortified by a resilient recurring revenue model.

Immix Biopharma heads to Morgan Stanley's key conference. Can its promising CAR-T therapy for AL Amyloidosis convince investors to fund the final mile?

The deal creating a North American abrasives leader is more than a simple merger; it's a strategic play by Speyside Equity to consolidate a key sector.

As JUNGSAEMMOOL enters Sephora, it's not just another K-Beauty launch. It's a calculated move signaling a market shift toward professional artistry.

Beneath stellar 38% revenue growth, Amex GBT's Q2 results reveal a strategy fueled by AI innovation, key client wins, and an impending private equity era.

As winter approaches, high-altitude homeowners face a hidden risk. Standard furnace care is dangerously inadequate in thin air, leading to costly failures.

Movie theaters are celebrating their biggest weekend in history, but behind the blockbuster numbers lies a more complex story of debt, strategy, and fragile hope.

As firms race to deploy AI agents, the security risks are exploding. Zero Networks' new solution aims to enforce control, turning a C-suite gamble into a calculated bet.

QHSLab flips to Q2 profit, driven by a recurring revenue model that's reshaping primary care. Is its strategic debt cleanup the key to sustainable growth?

MetLife Investment Management's latest fund isn't just another capital raise; it's a masterclass in strategic portfolio optimization via the secondary market.

From Amazon retail to darknet intelligence, Nexera's LOI with Nebo signals a bold pivot. Can this bet on proactive data center security redefine its future?

As enterprises grapple with data leaks from AI tools, Bold Security's new on-device solution aims to secure the last mile: the user's own machine.

Amid critical pharmacy shortages, one firm's award reveals the vital role of specialized staffing in keeping our healthcare system afloat. Here's why.

Etsy's divestiture of Depop to eBay is more than a sale; it's a strategic reset. We explore the why behind this billion-dollar e-commerce shake-up.